SNT 2.22% 4.4¢ syntara limited

Ann: Pharmaxis Announces LOXL2 Program Phase 2 Ready, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,135 Posts.
    lightbulb Created with Sketch. 546

    Surprisingly the share price is still not moving much.

    Synairgen has only 15% interest in the LOXL2 and Pharmaxis has 85%, but yesterday Synairgen rose 18%.

    This company has cash, products already on the market, existing NASH deal with pharmas potentially bring in hundreds of millions of payment, and the MC is still at 100m.



 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.